Research programme: monoclonal antibody therapeutics - A-CUBE/Chugai Pharmaceutical
Latest Information Update: 20 Dec 2010
At a glance
- Originator A-CUBE
- Developer A-CUBE; Chugai Biopharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase Unknown Unspecified
Most Recent Events
- 15 Dec 2010 Investigation in Undefined indication in USA (unspecified route)